RCM
ARQT icon

Regency Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Regency Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,000
Closed -$69K – 52
2023
Q3 		$69K Hold
13,000
– – 0.06% 44
2023
Q2 		$124K Buy
+13,000
New +$144K 0.11% 43

Other funds holding ARQT

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Regency Capital Management's ARQT Position: Q4 2023 in Review

Regency Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2023, closing a stake of 13,000 shares — an estimated $69K sold.

Regency Capital Management first reported a position in ARQT in Q2 2023 and held it in 2 quarters. The position peaked at $124K in Q2 2023. 133 funds tracked by Wall St. Rank hold ARQT as of Q4 2023.

  • Regency Capital Management reported no remaining Arcutis Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Regency Capital Management sold 13,000 Arcutis Biotherapeutics shares in Q4 2023, an estimated $69K.
  • Regency Capital Management first reported a position in Arcutis Biotherapeutics in Q2 2023 and held it in 2 quarters.
  • Regency Capital Management's Arcutis Biotherapeutics position peaked at $124K in Q2 2023.
  • 133 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2023.

Based on Regency Capital Management's 13F filing for Q4 2023, filed 23 Jan 2024.